Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial
- 1 January 2012
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 379 (9811) , 123-129
- https://doi.org/10.1016/s0140-6736(11)61505-5
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosisJournal of Thrombosis and Haemostasis, 2011
- Surveillance for Deep Vein Thrombosis and Pulmonary EmbolismAmerican Journal of Preventive Medicine, 2010
- Reversibility of the anti‐FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusionJournal of Thrombosis and Haemostasis, 2010
- Dabigatran versus Warfarin in the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2009
- The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trialsJournal of Thrombosis and Haemostasis, 2009
- Pharmacology and Management of the Vitamin K AntagonistsChest, 2008
- Antithrombotic Therapy for Venous Thromboembolic DiseaseChest, 2008
- Extended Prophylaxis of Venous Thromboembolism with IdraparinuxNew England Journal of Medicine, 2007
- Idraparinux versus Standard Therapy for Venous Thromboembolic DiseaseNew England Journal of Medicine, 2007
- Trends in the Incidence of Deep Vein Thrombosis and Pulmonary EmbolismArchives of internal medicine (1960), 1998